Enara Bio
Joe joined Enara Bio in 2019 following leadership across research and early development of novel immunotherapies, having led molecules from early discovery and validation through to first-in-human clinical studies.
Prior to joining Enara Bio, Joe spent eight years at Immunocore, developing novel TCR-based bispecific therapeutics. During this time, he established a bespoke, in vitro preclinical approach for generating safety data to de-risk TCR-based therapeutics. In his role as Head of Biology, Joe oversaw TCR discovery, characterisation, and preclinical screening of drug candidates. In addition, Joe was Program Leader for the second TCR-bispecific molecule to enter the clinic, leading cross-functional teams from early discovery in research, through preclinical and clinical development to successful IND/CTA submissions and first-in-human Phase 1 studies.
Joe obtained a PhD in Cell Biology and a subsequent post-doctoral fellowship at The University of Bath.
This person is not in any offices
Enara Bio
Enara Bio’s mission is to shine a light on unconventional targets and develop the next generation of cancer immunotherapies designed to treat a broad patient population. Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from altered cellular processes in cancer cells.